Immunotherapy beyond progression in patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer

Published:2020-12 Issue:6 Volume:9 Page:2391-2400
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Ge Xiangwei,Zhang Zhibo,Zhang Sujie,Yuan Fang,Zhang Fan,Yan Xiang,Han Xiao,Ma Junxun,Wang Lijie,Tao Haitao,Li Xiaoyan,Zhi Xiaoyu,Huang Zhiyue,Hofman Paul,Prelaj Arsela,Banna Giuseppe Luigi,Mutti Luciano,Hu Yi,Wang Jinliang

Publisher

AME Publishing Company

Subject

Oncology

Link

http://tlcr.amegroups.com/article/download/47598/pdf

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer;BMC Cancer;2024-05-07

2. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review;Chinese Clinical Oncology;2024-04

3. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study;Frontiers in Oncology;2024-02-12

4. Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study;Scientific Reports;2024-01-28

5. Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer;Clinical and Translational Oncology;2023-12-25